EBR Systems (EBR) Q1 2026 TU earnings summary

Executive summary

• Commercial case volumes more than doubled in Q1 2026 compared to Q4 2025, reflecting strong momentum for the WISE System.

• 41 commercial patients received the WISE System in Q1 2026, bringing total implants to 71 across pilot and Limited Market Release phases.

• 16 new purchase agreements were signed and 22 additional physicians trained during the quarter, supporting broader adoption.

• Clinical initiatives advanced with further enrollment in the WISE-UP post-approval study and TLC-AU feasibility study.

Financial highlights

• Preliminary unaudited Q1 2026 revenue expected between US $2.25M and US $2.36M, subject to closing adjustments.

Outlook and guidance

• Focus remains on disciplined execution, physician training, site activation, and building a foundation for broader adoption of the WISE System.

• Management expresses confidence in continued commercial and clinical progress.